Appeals Court to Review Limits on Mailing Abortion Pill mifepristone
The 5th U.S. Circuit Court will hear arguments on whether to reinstate restrictions on mailing mifepristone, a drug used for medication abortions.
Lawyers will argue before the New Orleans-based 5th Circuit about restoring limits on the mail distribution of mifepristone, a policy introduced during the Biden administration. Critics say the rule lacks a thorough safety review, while the Trump administration has asked courts to wait for an FDA assessment. Louisiana is also seeking to block shipments, claiming they weaken its near-total abortion ban.
Why it matters
The decision will affect nationwide access to medication abortions and the legal authority of federal health regulations.
How the sides frame it
MODERATE AGREEMENTLeft-leaning coverage frames the case as a legal review of stricter prescribing requirements and notes the FDA’s ongoing safety study, while right-leaning coverage frames it as a challenge to the Biden administration’s mail-distribution policy, emphasizing safety-review criticisms and political opposition.
LEFT
Focuses on the appellate court hearing a lawsuit seeking tighter prescribing rules and mentions the FDA’s study and Supreme Court’s stay
RIGHT
Portrays the case as an effort to reinstate limits on mailing the drug, criticizing the Biden policy’s safety review and highlighting political opposition
The left emphasises
- tighter prescribing rules for mifepristone
- panel includes judges appointed by Democratic and Republican presidents
- Supreme Court stayed any changes pending review
- FDA announced a study of mifepristone’s safety
The right emphasises
- restoring limits on mail distribution of mifepristone
- policy introduced during the Biden administration
- critics say the rule lacks a thorough safety review
- Trump administration asked courts to wait for an FDA assessment
In this story
